IL6R Gene Test (Interleukin 6 Receptor, Inflammation & Cardiometabolic Risk)

• Identify whether you carry IL6R variants such as Asp358Ala (rs2228145) that change the balance between membrane-bound IL-6 signalling and soluble IL-6 receptor (sIL-6R) levels, with downstream effects on inflammation markers.
• Help explain why your CRP or other inflammatory markers run higher or lower than expected, and how strongly lifestyle or therapies might move your inflammatory set point.
• Inform how aggressively to target inflammation in cardiovascular and metabolic prevention, autoimmunity risk, and healthy-ageing strategies.
• Provide context for how your immune system may respond to infections, tissue injury and chronic stress, and for how IL-6R-targeting treatments might behave in a clinical setting.
• Clarify your IL-6 signalling profile alongside IL-6, sIL-6R, CRP and cardiometabolic markers, so long-term prevention and performance plans can be tailored to your biology.

IL6R encodes the interleukin 6 receptor alpha chain, also known as CD126, a type I cytokine receptor that binds IL-6 with low affinity. To signal, IL-6 must bind IL6R and then recruit a second receptor subunit called gp130 (also known as IL6ST), forming a signalling complex that activates intracellular pathways such as JAK/STAT, MAPK and PI3K.

There are two major forms of IL-6 receptor: a membrane-bound form expressed on specific cells, including hepatocytes and some immune cells, and a soluble form (sIL-6R) that is generated by alternative splicing and by proteolytic shedding of the membrane receptor. Genetic variation in IL6R, particularly at the Asp358Ala site, influences how much membrane receptor is present and how much soluble receptor is produced.

IL6R sits at the core of how cells sense and respond to IL-6. When IL-6 binds to membrane-bound IL6R on cells that also express gp130, it triggers "classic signalling," which is important for acute-phase responses in the liver, regulation of immune cell differentiation and many regenerative processes. This pathway is restricted to cells that express membrane IL6R.

When IL-6 binds to soluble IL-6R in the circulation, the IL-6/sIL-6R complex can bind gp130 on virtually any cell, even if it does not express membrane IL6R, in a process called IL-6 "trans-signalling." Trans-signalling is thought to mediate many of the pro-inflammatory and pro-atherogenic actions of IL-6 in the vascular wall and other tissues. The Asp358Ala variant increases shedding and production of sIL-6R and lowers surface IL6R, altering the balance between classic and trans-signalling and changing downstream biology and disease risk.

IL6R contributes to three interconnected systems: acute and chronic inflammatory responses, cardiometabolic and vascular risk, and autoimmune and other inflammatory diseases. IL-6 signalling via IL6R is central to the acute-phase response, regulation of CRP and fibrinogen, and orchestration of innate and adaptive immune reactions.

Common IL6R variants have been associated with altered risk of coronary heart disease, atrial fibrillation, abdominal aortic aneurysm, rheumatoid arthritis and asthma in large human genetic studies. The Asp358Ala allele that increases sIL-6R and modifies IL-6 signalling appears to reduce risk of several cardiovascular and autoimmune conditions while increasing susceptibility to some atopic and inflammatory airway diseases. These patterns have helped validate IL6R as a therapeutic target and explain why IL-6R-blocking drugs can reduce inflammation-driven disease.

It is easy to assume that IL6R genotyping and IL-6 or CRP blood tests provide the same information, but they speak to different levels of biology. IL6R genotyping looks at inherited variants that alter the receptor's structure, expression and shedding, and therefore shape IL-6 signalling potential across your life. This does not fluctuate with current health or lifestyle, although its effects are strongly modified by environment.

IL-6, sIL-6R and CRP blood tests measure how your inflammatory and acute-phase systems are behaving now. These markers change rapidly with infection, stress, obesity, sleep, exercise and disease activity. You can carry a protective IL6R genotype yet still have high CRP if lifestyle or disease drivers are strong, and you can have a higher-risk genotype but low inflammatory markers if you maintain favourable metabolic, vascular and lifestyle profiles. Both genotype and serial inflammatory markers are useful when building a prevention strategy.

The influence of IL6R variants is shaped by body composition, lifestyle, co-existing conditions and medications. Several modifiable factors can either buffer genetic effects or magnify them.

• Adiposity and metabolic health: Visceral fat and insulin resistance increase IL-6 production and CRP, which can overshadow modest genetic differences in IL6R. Weight management and improved metabolic health can substantially reduce inflammation regardless of genotype.
• Diet and glycaemic control: Diets high in ultra-processed foods, refined carbohydrates and certain fats promote chronic low-grade inflammation, while whole-food patterns rich in plants, fibre, omega-3 fats and polyphenols tend to lower IL-6 and CRP.
• Physical activity and fitness: Regular physical activity lowers long-term inflammation and improves endothelial function, even though IL-6 can rise transiently with acute exercise. Sedentary behaviour amplifies IL-6-driven risk.
• Smoking, pollution and sleep: Smoking, air pollution, poor sleep and chronic stress increase inflammatory tone and can interact with IL6R-related signalling differences.
• Autoimmune, infectious and inflammatory diseases: Active autoimmune disease, chronic infection and other inflammatory disorders raise IL-6 and CRP markedly. In these settings, IL6R genotype is one factor among many determining disease course and treatment response.
• Medications and targeted therapies: Statins, some antihypertensives, anti-inflammatory drugs and IL-6/IL-6R-targeting biologics all modulate IL-6 pathways. Their effects may be influenced by IL6R background but remain powerful levers in their own right.

Yes. Many people carry IL6R variants such as Asp358Ala without any obvious inflammatory or cardiovascular symptoms. The gene shifts probabilities and patterns of risk rather than producing a single, recognisable syndrome.

Small differences often appear only when large groups are compared or when other risk factors are present. For individuals, IL6R variants may contribute to why one person in a high-risk environment develops coronary disease or rheumatoid arthritis while another does not, even when lifestyle looks similar on the surface.

IL6R genotypes mainly differ at regulatory and coding variants that alter receptor shedding, soluble receptor levels and cell-surface expression. The most studied variant is Asp358Ala (rs2228145).

• Asp358Ala (rs2228145): The Ala allele increases ADAM-mediated shedding of the membrane receptor, raises circulating sIL-6R by around one-third and reduces surface IL6R expression on certain immune cells. This impairs classical IL-6 signalling, increases IL-6 buffering in the circulation and is associated with lower levels of inflammatory biomarkers and reduced risk of several cardiovascular and autoimmune diseases, but higher risk of some asthma and atopic phenotypes.
• Other IL6R variants: Additional polymorphisms can fine-tune IL6R expression and splicing, but their effects are generally smaller or more context specific than Asp358Ala.
• Haplotype patterns and interaction with IL6 variants: IL6R polymorphisms interact with IL6 and other cytokine genes to shape overall inflammatory tone and disease susceptibility, supporting a network-level view rather than a single-gene interpretation.

For DNA-based IL6R testing, preparation is straightforward because genotype does not change with infections, diet or medications. The important step is deciding how the results will guide your inflammatory and cardiovascular strategy, rather than testing out of curiosity alone.

Cheek swab, saliva or blood-based IL6R genotyping does not require fasting. If you are also having IL-6, CRP, lipids, glucose or other blood tests, follow the preparation instructions for those, which may include fasting, avoiding strenuous exercise immediately beforehand, and scheduling the test at a time when you are not acutely unwell if you want a baseline reading.

An IL6R test is most useful when the result will influence how you interpret and act on inflammatory and cardiovascular risk, or when IL-6/IL-6R-targeted therapies are being considered. It becomes most informative when combined with clinical history, blood markers and other risk data.

• Borderline or persistent inflammation: If hs-CRP or IL-6 remain elevated despite lifestyle changes, IL6R genotyping can help distinguish genetic baseline from modifiable drivers and support decisions about how intensively to target inflammation.
• Strong family history of cardiovascular or autoimmune disease: In families with premature coronary disease, stroke or autoimmunity, IL6R and related genes add nuance to risk profiling and may justify earlier or more aggressive prevention.
• Complex cardiometabolic or inflammatory profiles: In people with metabolic syndrome, obesity, autoimmune conditions or multiple overlapping risk factors, IL6R status and inflammatory markers help refine risk communication and track response to interventions.
• Comprehensive prevention and longevity planning: For individuals building broad DNA and blood testing programmes, IL6R sits alongside IL6, CRP and TNF as a central lever in inflammation-centred prevention and healthy ageing.